改进我们评估已批准药物毒性的方式。 - Suppr

Suppr

超能文献

Improving how we evaluate the toxicity of approved drugs.

作者信息

Reidenberg Marcus M

机构信息

Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA.

出版信息

Clin Pharmacol Ther. 2006 Jul;80(1):1-6. doi: 10.1016/j.clpt.2006.03.006. Epub 2006 Jun 8.

DOI:10.1016/j.clpt.2006.03.006

PMID:16815311

Abstract

摘要

相似文献

Improving how we evaluate the toxicity of approved drugs.

Clin Pharmacol Ther. 2006 Jul;80(1):1-6. doi: 10.1016/j.clpt.2006.03.006. Epub 2006 Jun 8.

A proposal for radical changes in the drug-approval process.

N Engl J Med. 2006 Aug 10;355(6):618-23. doi: 10.1056/NEJMsb055203.

Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.

J Clin Pharmacol. 2007 Sep;47(9):1074-86. doi: 10.1177/0091270007304776.

Clinical trials and public trust.

Science. 2004 Dec 3;306(5702):1649. doi: 10.1126/science.1107657.

How experimental drugs are tested in humans.

Pediatr Infect Dis J. 1989 Mar;8(3):160-2.

Beware of new drugs, study suggests.

Rep Med Guidel Outcomes Res. 2002 May 17;13(10):1-2, 5.

The pharmacist and adverse drug reaction reporting.

Hosp Pharm. 1982 Aug;17(8):421-2, 427-30.

Adverse drug event reporting. Improving the low US reporting rates.

Arch Intern Med. 1988 Jul;148(7):1499-503.

Systematic identification of drugs that cause birth defects--a new opportunity.

N Engl J Med. 2003 Dec 25;349(26):2556-9. doi: 10.1056/NEJMsb031395.

Making all clinical trials available for review: any impact on clinical decisions?

J Am Pharm Assoc (2003). 2005 Jan-Feb;45(1):7-8.

引用本文的文献

Gap in publication of comparative information on new medicines.

Br J Clin Pharmacol. 2008 May;65(5):716-22. doi: 10.1111/j.1365-2125.2007.03092.x. Epub 2008 Feb 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Improving how we evaluate the toxicity of approved drugs.

Clin Pharmacol Ther. 2006 Jul;80(1):1-6. doi: 10.1016/j.clpt.2006.03.006. Epub 2006 Jun 8.

A proposal for radical changes in the drug-approval process.

N Engl J Med. 2006 Aug 10;355(6):618-23. doi: 10.1056/NEJMsb055203.

Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.

J Clin Pharmacol. 2007 Sep;47(9):1074-86. doi: 10.1177/0091270007304776.

Clinical trials and public trust.

Science. 2004 Dec 3;306(5702):1649. doi: 10.1126/science.1107657.

How experimental drugs are tested in humans.

Pediatr Infect Dis J. 1989 Mar;8(3):160-2.

Beware of new drugs, study suggests.

Rep Med Guidel Outcomes Res. 2002 May 17;13(10):1-2, 5.

The pharmacist and adverse drug reaction reporting.

Hosp Pharm. 1982 Aug;17(8):421-2, 427-30.

Adverse drug event reporting. Improving the low US reporting rates.

Arch Intern Med. 1988 Jul;148(7):1499-503.

Systematic identification of drugs that cause birth defects--a new opportunity.

N Engl J Med. 2003 Dec 25;349(26):2556-9. doi: 10.1056/NEJMsb031395.

Making all clinical trials available for review: any impact on clinical decisions?

J Am Pharm Assoc (2003). 2005 Jan-Feb;45(1):7-8.

引用本文的文献

Gap in publication of comparative information on new medicines.

Br J Clin Pharmacol. 2008 May;65(5):716-22. doi: 10.1111/j.1365-2125.2007.03092.x. Epub 2008 Feb 21.